James Huang's appointment to Connect Biopharma's Board of Directors is viewed positively, with his vast biotech and investment experience anticipated to offer unique insights and aid the company's pipeline progression.
FiReBiTriXiE :
Why short good news? You think they’d want it to go up them short it there’s more meat on the bones then but like everything in the market rich dumb fucks have to own run and control every aspect it’s like the bully at school or the spoiled brat friend that invites you to come over and play only to keep all his toys to himself and play with em right In front of you!! It’s retarded Asf and lame and maes nobody want to play frfr idiots
$康乃德生物(CNTB.US)$ To report possible manipulation in a stock to the U.S. Securities and Exchange Commission (SEC), you can follow these steps: 1. Visit the SEC's official website atwww.sec.gov. 2. Look for the "File a Complaint" or "Report Misconduct" section on the SEC's website. This section may be located under the "Enforcement" or "Investor Information" tab. 3. Follow the instructions provided to file a c...
FiReBiTriXiE楼主I love me:
Probably nothing it’s the SEC ffs they probs the Dons of it all you know fck hate em all rich greedy fcks will be sitting on the devils tho that’s a for sure fact haha
$康乃德生物(CNTB.US)$Connect Biopharma Announces Rademikibart Global Phase 2b Topline Results in Adult Patients With Moderate-to-Severe Persistent Asthma announced today positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma Benzinga· 1 min ago
Trytosaveabit楼主Zahid007:
Yeah I see! But you can’t get a true idea of what the market will think until open! A lot of times you don’t know the true liquidity of a ticker during PM and AM? That’s what makes trading during them risky! GL
$康乃德生物(CNTB.US)$insiders going to pump this stock for the next three days since there is a big new coming out .. lots of groups already recommended buy signal also look at the indicators strong bullish signals
$康乃德生物(CNTB.US)$Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
Despite Connect Biopharma Holdings' promising cash runway and reduced cash burn, the company's high expenditure relative to its market value makes its cash burn situation appear risky.
康乃德生物股票讨论区
Price target for this stock is 7$ its undervalued .. sooner it will jump to 2.5 to 3$
Real peachy😁🖕🏼
If you want to report any suspected illegal practices to the SEC here ya go…
To report possible manipulation in a stock to the U.S. Securities and Exchange Commission (SEC), you can follow these steps: 1. Visit the SEC's official website at www.sec.gov. 2. Look for the "File a Complaint" or "Report Misconduct" section on the SEC's website. This section may be located under the "Enforcement" or "Investor Information" tab. 3. Follow the instructions provided to file a c...
News 📰
Update
announced today positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma
Benzinga· 1 min ago
also look at the indicators strong bullish signals
Update
暂无评论